Molecular Imaging Agent facilitates disease research.August 27, 2008 -
With IntegriSense(TM) Fluorescence Molecular Imaging Agent, researchers can image and assess role of integrin alpha v beta 3 in disease progression and therapeutic response in disease states including oncology, cardiovascular disease, and bone disease. Agent works with VisEn's Quantitative Tomographic FMT imaging systems to enable quantitative data on biological targets in vivo. It is also compatible with other fluorescence imaging systems, including planar systems and intravital microscopes.
(Archive News Story - Products mentioned in this Archive News Story may or may not be available from the manufacturer.)
Original Press release
VisEn Medical, Inc.
45 Wiggins Avenue
Bedford, MA, 01730
USA
VisEn Announces Commercial Launch of IntegriSense(TM) Fluorescence Molecular Imaging Agent
- First Product Developed from the VisEn-Merck & Co., Inc. Biomarker Imaging Program -
- Expands VisEn's Leading Fluorescence Molecular Imaging Agent Portfolio and Broadens Applications in Key Areas of Disease Research and Drug Development -
BEDFORD, Mass., Aug. 19 /- VisEn Medical, Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its IntegriSense(TM) fluorescence in vivo imaging agent product line. The agent is the first product developed out of the Merck-VisEn Biomarker Imaging research collaboration announced in 2007, and will enable researchers to image and assess the role of integrin alpha v beta 3 in disease progression and therapeutic response in vivo.
IntegriSense is an optimized in vivo fluorescence imaging agent targeting integrin alpha v beta 3, a key biomarker closely associated with disease-related vascularity and angiogenesis. The agent was developed to enable in vivo imaging of integrin alpha v beta 3 expression in order to measure and monitor aspects of disease progression and therapeutic response in disease states including oncology, cardiovascular disease, and bone disease.
"The integrin alpha v beta 3 protein plays an important key role in many disease pathways, which is one of the key reasons we selected this as a first imaging target with our collaborators at Merck," said Kirtland Poss, President and CEO of VisEn Medical. "IntegriSense should enable researchers to drive valuable new insights into disease progression and therapeutic mechanisms of action in vivo. We are pleased to be providing our customers the continually expanding ability to generate such rich information on their disease biologies and pathways of interest."
VisEn's in vivo fluorescence imaging technologies, including its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomographic Imaging Systems (FMT), provide the industry's most robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers in vivo. All of the VisEn imaging agents are designed for use with VisEn's Quantitative Tomographic FMT imaging systems to enable quantitative data on biological targets in vivo. They are also compatible with a range of additional fluorescence imaging systems, including planar systems and intravital microscopes.
Additional product information can be obtained by calling Customer Support at VisEn Medical: 781-932-6875, ext. 315, via email at: info@visenmedical.com; or at www.visenmedical.com.
About VisEn Medical
VisEn Medical develops and commercializes the industry's highest performing fluorescence in vivo imaging technology platforms, from research through medicine. Founded in 2000 based on fluorescence in vivo imaging technologies developed by industry-leading researchers and clinicians at the Massachusetts General Hospital and Harvard Medical School, VisEn's FMT Fluorescence Tomography imaging systems and suite of molecular imaging agents are used to quantify biological mechanisms of disease and therapeutic response in vivo. These systems are widely used by leading research institutions and pharmaceutical companies in disease areas including oncology, inflammation, cardiovascular, skeletal and pulmonary diseases. The Company also works with pharmaceutical and clinical partners to design and develop ranges of tailored molecular imaging agents and applications that are targeted to their specific pre-clinical and clinical research areas. For further information please visit www.visenmedical.com.
CONTACT: Robert Sandler, VP, Marketing of VisEn Medical Inc., O.
+1-647-350-1881, C. +1-416-274-8166, rsandler@visenmedical.com; or Peter
Steinerman, Principal of Steinerman Biomedical Comm. For VisEn Medical Inc., O. +1-516-374-3031, C. 516 641 8959, PRSteinerman@aol.com
Web Site: http://www.visenmedical.com/
|
|
|
|
|
|
|
| 
